Article Text

PDF
POMD07 Quantitative assessment of biological and clinical manifestations of Huntington's disease before and after diagnosis—the TRACK-HD study
  1. N Lahiri1,2,3,
  2. S J Tabrizi1,2,3,
  3. C Kennard1,2,3,
  4. A Durr1,2,3,
  5. B R Leavitt1,2,3,
  6. N Fox1,2,3,
  7. R A Roos1,2,3
  1. 1National Hospital for Neurology and Neurosurgery, UCL Institute of Neurology, London, UK
  2. 2Track-HD Investigators, University College London, London, UK
  3. 3Oxford University, Oxford, UK
  1. Correspondence to n.lahiri{at}ion.ucl.ac.uk

Abstract

Background Huntington's disease (HD) is a fully penetrant dominantly inherited neurodegenerative disease. The aim of this study was to identify sensitive and reliable biomarkers in clinically premanifest HD gene carriers and early HD patients.

Methods TRACK-HD is a multinational longitudinal observational study that uses an extensive battery of assessments including 3-T MR imaging, clinical, cognitive, quantitative motor, oculomotor and neuropsychiatric measures. Blinded analysis was performed on the baseline cross-sectional data which included 366 subjects (123 controls, 123 early HD, 120 premanifest subjects).

Results Cross-sectional analysis identified significant changes in whole-brain volume, regional grey and white matter, impairment in a range of voluntary motor physiology and oculomotor tasks, cognitive and neuropsychiatric dysfunction in premanifest HD gene carriers through to early clinical stage II disease.

Conclusions Our results provide evidence for quantifiable biological and clinical alterations in HD expansion carriers compared to age-matched controls. Many parameters differ from age-matched controls in a graded fashion showing changes of increasing magnitude covering two decades of disease development from pre-HD up to ∼16 years from predicted onset through to HD stage II. These findings help to define novel quantifiable endpoints and methods for rapid and reliable multisite data acquisition that form the essential foundation to design therapeutic trials.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.